8 results about "Cell death rate" patented technology

The invention relates to the technical field of gene engineering, in particular to SgRNA for targeted knockout of an MINOS1 gene and application of the SgRNA. According to the invention, a CRISPR / Cas9 gene knockout technology is adopted, a LentiCRISPR-V2 vector is constructed by using a CRISPR / Cas9 system, the LentiCRISPR-V2 vector is co-transferred into a porcine small intestine epithelial cell to obtain a positive cell clone, an MINOS1 gene in the positive cell clone is not expressed, the cell death rate under a hypoxia condition can be obviously reduced, and the positive cell clone has hypoxia tolerance. By regulating and controlling MINOS1 expression, the adaptive capacity of an organism to a low-oxygen environment can be enhanced, and a new thought is provided for preventing and relieving altitude stress and improving physiological tolerance in an extreme environment; besides, the hypoxia characteristic of the tumor microenvironment is a key factor causing chemoradiotherapy drug resistance, and the MINOS1 knockout related strategy can reverse the hypoxia tolerance phenotype of tumor cells, so that the sensitivity of the tumor cells to treatment is enhanced, and an innovative direction is provided for overcoming tumor drug resistance.

This invention provides a liquid drug for the prevention and treatment of viral infections in chickens, belonging to the field of veterinary medicine. The liquid drug uses a polypeptide from chicken cartilage as its active ingredient, with the amino acid sequence Gly-Glu-Glu-Gly-Thr-Met-Gly-Leu, and is prepared into solutions with concentrations ranging from 6.25 μg / mL to 100 μg / mL using PBS buffer as a solvent. Experimental results show that this drug can significantly reduce cell death and chicken embryo mortality caused by viral infection by preventing H9N2 virus infection and inhibiting viral replication in host cells, and prolong the survival time of infected individuals. The liquid drug provided by this invention is highly effective, safe, and easy to use, and is suitable for the prevention and control of viral infections in chicken flocks in large-scale poultry farms.

The application belongs to the technical field of biotechnology, and particularly relates to a research method for reducing an animal model of lipopolysaccharide acute lung injury through a SCAP / SREBP2 / NLRP3 pathway by quercetin, which comprises the following steps: S1, grouping and processing of experimental animals; S2, cell culture and grouping thereof; S3, lung wet / dry ratio (W / D) of the experimental animals is evaluated to assess lung edema and bronchoalveolar lavage fluid (BALF) is collected; S4, lung tissue pathology of the experimental animals is observed; S5, ELISA is used to detect levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta); S6, Western blot is used to detect pathway proteins; S7, qPCR is used to detect expression of related nucleic acids; S8, flow cytometry is used to detect cell mortality, and statistical processing is performed using GraphPad Prism 9.0 software for statistical analysis. The application expresses the role of quercetin in mouse acute lung injury and the regulation and influence of the SCAP / SREBP2 / NLRP3 pathway-mediated inflammatory response through an experimental method, thereby providing a theoretical basis for treatment of ARDS.

The embodiment discloses an optical density measurement and testing including a purification device that separates live cancer cells from dead and non-cancer cells of a microbiology sample. A drug addition device and a drug dosage sequencer introduce controlled dosages of at least one drug treatment into the live cancer cells. An optical density measurement device with an optical sensor captures high-resolution images of the live cells at predetermined intervals, and an optical spectrophotometric reader quantifies cell populations following treatment. A flow cytometry device measures fluorescent intensities of immune checkpoint markers and tumor antigens to generate immune system activation profiles. A processor subsystem analyzes cell death rates and immune responses to create integrated drug response profiles, and a computer application compares these results with patient-specific genetic and clinical data to produce personalized treatment recommendations.

The invention belongs to the technical field of biological medicines, and particularly discloses application of low-concentration recombinant human periostin in preparation of a medicine for treating intervertebral disc degeneration. The invention provides application of low-concentration recombinant human periostin in preparation of a medicine for treating intervertebral disc degeneration. The invention provides application of low-concentration recombinant human periostin in preparation of a medicine for treating intervertebral disc degeneration. The low-concentration recombinant human periostin can remarkably reduce the death rate of intervertebral disc nucleus pulposus cells induced by TNF-alpha, effectively relieve oxidative stress injury, up-regulate the expression of Collagen II and Aggrecan, down-regulate the expression of MMP 13, promote cell proliferation and treat intervertebral disc degeneration.

The invention discloses a natural compound for inhibiting disulfide death by taking VAV3 as a target spot and application of the natural compound. Belongs to the technical field of biological medicine and pharmacy. According to the invention, through virtual screening and surface plasmon resonance technologies, seven small molecular compounds, including kaempferol, liensinine, sophocarpidine, isorhamnetin, deoxyshikonin, harmine and potenoside, which can be specifically bound with VAV3 protein are screened from a natural product library for the first time. In a C2C12 cell insulin resistance model, the compounds can significantly reduce the cell death rate caused by disulfide death, and the action mechanism of the compounds is to improve the activity or expression of VAV3, inhibit abnormal accumulation of cystine and improve the NADPH level, thereby effectively preventing disulfide bond crosslinking and collapse of an actin filament network. Experiments show that the compound provided by the invention can effectively inhibit disulfide death of skeletal muscle cells by targeting VAV3, and a new lead compound and a solution are provided for developing drugs for treating diabetic muscle dysfunction and related metabolic diseases.

The invention discloses a method for improving cell hypoxia tolerance by knocking out a PAXIP1 gene, belongs to the field of gene engineering, and proves that the PAXIP1 gene knockout can remarkably enhance the hypoxia toxicity resistance of cells to CoCl2 induction for the first time by constructing a pig small intestine epithelial cell model with the PAXIP1 gene knockout. The cell death rate of a gene knockout group is remarkably reduced, and the cell survival rate is remarkably improved. The result shows that PAXIP1 gene knockout can activate an anti-hypoxia protection mechanism of porcine small intestine epithelial cells, and reveals direct association between the PAXIP1 gene and animal hypoxia adaptability. The invention provides a new key functional gene target for high-altitude hypoxia adaptability research, and has potential application value in the fields of animal breeding and hypoxia-related disease treatment.

This invention provides a method, system, and electronic device for detecting and controlling the liquid temperature of a wave-shaped reactor reaction bag. The method includes acquiring the center temperature of the reaction bag using a center temperature sensor located at the center of the heating tray, and acquiring the platform temperature of the reaction bag using a platform temperature sensor located on the outer ring of the heating tray. The center temperature is taken as value A, and the platform temperature is taken as value B, and a calculated center temperature value C is obtained, where C = (A + B) / 2. A temperature control module calculates the target platform temperature value using value C. The target platform temperature value is compared with value B to calculate the duty cycle of the heating output, thereby controlling the heating temperature of the heating tray. This invention achieves the effects of small temperature detection difference, low cell death rate, or rapid cell growth.